# Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

> **NCT00234442** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 47 (—)

## Conditions studied

- Brain Neoplasms
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Iressa (Gefitinib)

## Key facts

- **NCT ID:** NCT00234442
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 47 (—)
- **Why stopped:** Closed due to insufficient recruitment.
- **Last updated:** 2009-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234442, "Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00234442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*